Clinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damage

Zhejinag University of f Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) meet the diagnostic criteria of RA, activity period and abnormal heart function;
•(2) between the ages of 18 and 60;
•(3) if taking NSAIDs, the dose has been stable for at least 4 weeks; if not, it has been stable for at least 1 week;
•(4) if you take MTX, you have been treated with MTX3 for at least 4 months, and the dose is fixed at 10mg/ week for at least 4 weeks.If you take LEF, you have been treated with leff for at least 3 months, and the dose is fixed at 10mg/ day for at least 4 weeks.
•(5) if glucocorticoid is taken, the dose (compared with prednisone) must be less than 15mg/ day and has been used for at least 4 weeks;
•(6) participate in the study voluntarily and sign the informed consent.

•(1) intramuscular injection or intravenous drip of glucocorticoids within 4 weeks;
•(2) das28-3 score > 5.1 (high activity);
•(3) patients with other rheumatic diseases such as systemic lupus erythematosus, sjogren's syndrome and gout;
•(4) pregnant or nursing women or those who plan to give birth in the near future;
•(5) allergic to the test drugs;
•(6) those who have participated in other clinical trials recently (within 1 month);
•(7) mental patients and people without capacity for civil conduct.

发起方

Zhejinag University of f Chinese Medicine